SEC Comment Letter 0000000000-23-007429 to Terns Pharmaceuticals, Inc. (TERN)

Terns Pharmaceuticals, Inc.
Date: July 12, 2023 · CIK: 0001831363 · Accession: 0000000000-23-007429

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-039926

Date

July 12, 2023

Author

Not clearly detected

Form

UPLOAD

Company

Terns Pharmaceuticals, Inc.

Letter

United States securities and exchange commission logo July 12, 2023 Mark Vignola Chief Financial Officer Terns Pharmaceuticals, Inc. 1065 East Hillsdale Blvd Suite 100 Foster City, CA 94404 Re:Terns Pharmaceuticals, Inc. Form 10-K for the Year Ended December 31, 2022 File No. 001-039926 Dear Mark Vignola: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
July 12, 2023
Mark Vignola
Chief Financial Officer
Terns Pharmaceuticals, Inc.
1065 East Hillsdale Blvd
Suite 100
Foster City, CA 94404
Re:Terns Pharmaceuticals, Inc.
Form 10-K for the Year Ended December 31, 2022
File No. 001-039926
Dear Mark Vignola:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io